Avalo Therapeutics
- Founded: 2011
- Location: Rockville, MD
- Employee range: 11 - 50
- Clinical stage: Clin3 (fast track)
- Therapy area: Leukocyte deficiency syndrome II (ODD)
- Drug types: HEM, GEN, INF, LNG, GI, IMM
- Lead product: AVTX-803
- Product link: https://www.avalotx.com/pipeline
- Funding: $15M stock Feb 2023; $31.5M stock Sep 2021; $36.4M stock Jan 2021
avalotx.com linkedin.com job board
Short description:
Small molecules for neuro / psychiatric disorders
Drug notes:
AVTX-002 Clin2 (fast track) COVID-19 ARDS, Clin2 (failed Jun 2023) non-eosinophilic asthma, Clin1 Crohn's; AVTX-008 RD/Clin0 immunoregulatory disorders
Long description:
Avalo Therapeutics is creating treatments for patients with unmet clinical needs in immunology and rare genetic diseases. At the core of Avalo’s therapeutics is immune regulation by targeting the LIGHT-signaling network. LIGHT is a newly recognised cytokine with inflammatory actions in the lung, gut and skin, encoded by the TNFSF14 gene. The LIGHT immune regulatory network is suggested to be dysregulated and a disease-driving mechanism in autoimmune and inflammatory reactions. By reducing signaling through the LIGHT-signaling network, Avalo hopes to moderate immune dysregulation. Avalo’s pipeline includes various biologics focused on dysregulated inflammation via the LIGHT-signaling network with several in clinical stages.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com